Extended indication Treatment of patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab therapy
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Pozelimab
Domain Cardiovascular diseases
Reason of inclusion New medicine (specialité)
Main indication Other non-oncological hematological medications
Extended indication Treatment of patients with paroxysmal nocturnal hemoglobinuria who switch from eculizumab therapy
Manufacturer Regeneron
Mechanism of action Unknown
Route of administration Intravenous
Therapeutical formulation Unknown
Budgetting framework Intermural (MSZ)
Additional remarks Complement C5 inhibitors

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date 2024
Expected Registration 2025
Orphan drug Unknown
Registration phase Clinical trials
Additional remarks NCT05131204

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Substantiation Er lopen nog diverse studies waarbij pozelimab gecombineerd wordt met eem siRNA cemdisiran.

Expected patient volume per year

Patient volume < 80

Market share is generally not included unless otherwise stated.

References Expertopinie (1)
Additional remarks Op basis van de gebruikersaantallen van eculizumab bij PNH patiënten wordt er verwacht dat er maximaal 80 patiënten in aanmerking komen indien er substitutie plaatsvindt.

Expected cost per patient per year

References drugs.com
Additional remarks De Amerikaanse prijs voor pozelimab is (bbfg 200mg/mL) $36,460 voor 2 milliliter. De prijs in de Verenigde Staten ligt vaak hoger dan de Nederlandse prijs.

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information